Metabolism of Growth Hormone Releasing Peptides - Kölner UniversitätsPublikationsServer

Thomas, Andreas ORCID: 0000-0003-1199-0743, Delahaut, Philippe, Krug, Oliver, Schaenzer, Wilhelm and Thevis, Mario (2012). Metabolism of Growth Hormone Releasing Peptides. Anal. Chem., 84 (23). S. 10252 - 10260. WASHINGTON: AMER CHEMICAL SOC. ISSN 1520-6882

Full text not available from this repository.

DOI:10.1021/ac302034w

Abstract

New, potentially performance enhancing compounds have frequently been introduced to licit and illicit markets and rapidly distributed via worldwide operating Internet platforms. Developing fast analytical strategies to follow these new trends is one the most challenging issues for modern doping control analysis. Even if reference compounds for the active drugs are readily obtained, their unknown metabolism complicates effective testing strategies. Recently, a new class of small C-terminally amidated peptides comprising four to seven amino acid residues received considerable attention of sports drug testing authorities due to their ability to stimulate growth hormone release from the pituitary. The most promising candidates are the growth hormone releasing peptide (GHRP)-1, -2, -4, -5, -6, hexarelin, alexamorelin, and ipamorelin. With the exemption of GHRP-2, the entity of these peptides represents nonapproved pharmaceuticals; however, via Internet providers, all compounds are readily available. To date, only limited information on the metabolism of these substances is available and merely one metabolite for GHRP-2 is established. Therefore, a comprehensive in vivo (po and iv administration in rats) and in vitro (with human serum and recombinant amidase) study was performed in order to generate information on urinary metabolites potentially useful for routine doping controls. The urine samples from the in vivo experiments were purified by mixed-mode cation-exchange solid-phase extraction and analyzed by ultrahigh-performance liquid chromatography (UHPLC) separation followed by high-resolution/high-accuracy mass spectrometry. Combining the high resolution power of a benchtop Orbitrap mass analyzer for the first metabolite screening and the speed of a quadrupole/time-of-flight (QTOF) instrument for identification, urinary metabolites were screened by means of a sensitive full scan analysis and subsequently confirmed by high-accuracy product ion scan experiments. Two deuterium-labeled internal standards (triply deuterated GHRP-4 and GHRP-2 metabolite) were used to optimize the extraction and analysis procedure. Overall, 28 metabolites (at least three for each GHRP) were identified from the in vivo samples and main metabolites were confirmed by the human in vitro model. All identified metabolites were formed due to exopeptidase- (amino- or carboxy-), amidase-, or endopeptidase activity.

Item Type:

Journal Article

Creators:

Creators	Email	ORCID	ORCID Put Code
Thomas, Andreas	UNSPECIFIED	orcid.org/0000-0003-1199-0743	UNSPECIFIED
Delahaut, Philippe	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Krug, Oliver	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Schaenzer, Wilhelm	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Thevis, Mario	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED